VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines

Status Completed

Clinical Trial Summary

This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection. The participants will receive one or two doses of ChAd63 PvDBP followed by one dose of MVA PvDBP 8 weeks later. Approximately 4 weeks after the second vacccination, the volunteers will be challenged (deliberately infected) with malaria by intravenous injection blood-stage

Clinical Trial Description

Volunteers will be recruited and vaccinated at the CCVTM, Oxford. There will be two groups vaccinated in the trial, with an optional third group included if fewer than 6 volunteers complete group 2. Up to 19 volunteers will be included in total. These will be compared to a matched number of infectivity controls, receiving no vaccination, who will be recruited as part of a separate study (VAC069 - NCT03797989). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04009096
Study type	Interventional
Source	University of Oxford
Contact
Status	Completed
Phase	Phase 2
Start date	July 18, 2019
Completion date	July 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05096702` - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting	`NCT05540470` - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield	N/A
Active, not recruiting	`NCT04079621` - Short Course Radical Cure of P. Vivax Malaria in Nepal	Phase 4
Completed	`NCT03307369` - A Retrospective Study of Severe Plasmodium Vivax
Completed	`NCT01213966` - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection	Phase 2
Completed	`NCT00811096` - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax	Phase 2
Terminated	`NCT03337152` - Assessing a Risk Model for G6PD Deficiency	Phase 4
Completed	`NCT05753150` - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed	`NCT02751294` - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution	Phase 1
Recruiting	`NCT05058885` - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed	`NCT03377296` - Study of Controlled Human Plasmodium Vivax Infection	N/A
Completed	`NCT00486694` - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria	Phase 2
Recruiting	`NCT05788094` - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection	Phase 4
Terminated	`NCT02110784` - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria	Phase 2
Not yet recruiting	`NCT05690841` - FocaL Mass Drug Administration for Vivax Malaria Elimination	Phase 3
Not yet recruiting	`NCT04739917` - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers	Phase 2
Completed	`NCT03208907` - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil	Phase 3
Completed	`NCT02184637` - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate	Phase 1
Completed	`NCT01928914` - Tafenoquine Thorough QTc Study in Healthy Subjects	Phase 1
Completed	`NCT01081847` - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants	Phase 1